Diabetes Mellitus and Alzheimer's Disease: The Protection of Epigallocatechin-3-gallate in Streptozotocin Injection-Induced Models
Diabetes mellitus is considered as a risk factor of Alzheimer's disease (AD), the front runner of neurodegenerative disorders. Streptozotocin (STZ) is a toxin for pancreatic β-cell, which can construct a model of insulin deficient diabetes through intraperitoneal or intravenous injection. A mod...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2017-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b34e3e59039d43b682cd63b5f748cd2f | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jin-Jing Jia |e author |
| 700 | 1 | 0 | |a Jin-Jing Jia |e author |
| 700 | 1 | 0 | |a Jin-Jing Jia |e author |
| 700 | 1 | 0 | |a Xian-Si Zeng |e author |
| 700 | 1 | 0 | |a Xian-Si Zeng |e author |
| 700 | 1 | 0 | |a Xian-Si Zeng |e author |
| 700 | 1 | 0 | |a Xin-Qiang Song |e author |
| 700 | 1 | 0 | |a Peng-Peng Zhang |e author |
| 700 | 1 | 0 | |a Lei Chen |e author |
| 245 | 0 | 0 | |a Diabetes Mellitus and Alzheimer's Disease: The Protection of Epigallocatechin-3-gallate in Streptozotocin Injection-Induced Models |
| 260 | |b Frontiers Media S.A., |c 2017-11-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2017.00834 | ||
| 520 | |a Diabetes mellitus is considered as a risk factor of Alzheimer's disease (AD), the front runner of neurodegenerative disorders. Streptozotocin (STZ) is a toxin for pancreatic β-cell, which can construct a model of insulin deficient diabetes through intraperitoneal or intravenous injection. A model generated by intracerebroventricular STZ (icv-STZ) also shows numerous aspects of sporadic AD. The protective roles of tea polyphenols epigallocatechin-3-gallate (EGCG) on both two diseases were researched by some scientists. This review highlights the link between diabetes and AD and recent studies on STZ injection-induced models, and also discusses the protection of EGCG to clarify its treatment in STZ-induced diabetes and AD. | ||
| 546 | |a EN | ||
| 690 | |a diabetes | ||
| 690 | |a Alzheimer's disease | ||
| 690 | |a streptozotocin | ||
| 690 | |a epigallocatechin-3-gallate | ||
| 690 | |a protection | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 8 (2017) | |
| 787 | 0 | |n http://journal.frontiersin.org/article/10.3389/fphar.2017.00834/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b34e3e59039d43b682cd63b5f748cd2f |z Connect to this object online. |